Key facts
- This page summarizes Burke Thomas Barrett's Form 4 filing for Pulse Biosciences, Inc. (PLSE).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 24 Jun 2024, 19:31.
Burke Thomas Barrett - 12 May 2024 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- PLSE
- Reported as of
- 12 May 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Jun 2024, 19:31:51 UTC
- Next SEC filing
- 22 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kenneth B. Stratton, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Burke Thomas Barrett filed Form 4 for Pulse Biosciences, Inc. (PLSE) on 24 Jun 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PLSE
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +700,000
- Change %
- Price
- $0.000000
- Shares after
- 700,000
- Date
- 12 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 700,000
- Exercise price
- $7.45
- Footnotes
- F1
PLSE
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +700,000
- Change %
- Price
- $0.000000
- Shares after
- 700,000
- Date
- 12 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 700,000
- Exercise price
- $7.45
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares will vest in four equal annual installments on each of the first four annual anniversaries of the grant date, subject to the Reporting Person's continued service through each vesting date.
Footnote F2
The shares subject to this option are subject to five tranches of performance-based vesting criteria tied to Issuer's market capitalization, with no vesting until the Issuer's market capitalization exceeds $1 billion, in all cases, subject to the Reporting Person's continued service through each vesting milestone.